AML

Faron’s Clever-1 drug shows promise in blood cancers
Faron’s Clever-1 drug shows promise in blood cancers
Pharmaphorum
Faron Pharmaceuticals
bexmarilimab
AML
MDS
clinical trials
Flag link:
Syndax stops pivotal cancer trial early for efficacy but details disappoint, sending stock down
Syndax stops pivotal cancer trial early for efficacy but details disappoint, sending stock down
Fierce Biotech
Syndax Pharmaceuticals
clinical trials
revumenib
AML
Flag link:
Mendus shows early comparability data for its universal cancer vaccine
Mendus shows early comparability data for its universal cancer vaccine
Clinical Trials Arena
Mendus
vididencel
AML
ovarian cancer
vaccines
Flag link:
Foghorn Therapeutics doses first patient in AML therapy trial
Foghorn Therapeutics doses first patient in AML therapy trial
Clinical Trials Arena
Foghorn Therapeutics
FHD-286
AML
Flag link:
Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet
Gilead's magrolimab once again placed on partial clinical hold, another setback for Forty Seven bet
Fierce Biotech
Gilead Sciences
MDS
magrolimab
clinical trials
AML
Flag link:
FDA puts 2seventy CAR-T trial on hold in wake of patient death
FDA puts 2seventy CAR-T trial on hold in wake of patient death
Fierce Biotech
2seventy bio
clinical trials
FDA
patient deaths
AML
CAR-T
Flag link:
FDA okays Daiichi Sankyo’s Vanflyta for first-line AML
FDA okays Daiichi Sankyo’s Vanflyta for first-line AML
Pharmaphorum
Daiichi Sankyo
Vanflyta
FDA
AML
Flag link:
Foghorn Abandons Uveal Melanoma Program after Subpar Phase I Results
Foghorn Abandons Uveal Melanoma Program after Subpar Phase I Results
BioSpace
Foghorn Therapeutics
uveal melanoma
AML
FHD-286
Flag link:
Kura files $100m offer after menin inhibitor results in AML
Kura files $100m offer after menin inhibitor results in AML
Pharmaphorum
Kura Oncology
ziftomenib
AML
stock offering
EHA
Flag link:
Death triggers pause of 2seventy CAR-T cell therapy leukemia trial
Death triggers pause of 2seventy CAR-T cell therapy leukemia trial
Fierce Biotech
2seventy bio
Bluebird Bio
CAR-T
patient death
clinical trials
AML
Flag link:
Mendus cancer vaccine succeeds in Phase II AML trial
Mendus cancer vaccine succeeds in Phase II AML trial
Clinical Trials Arena
Mendus
vididencel
AML
clinical trials
Flag link:
Affimed begins subject dosing in acute myeloid leukaemia therapy trial
Affimed begins subject dosing in acute myeloid leukaemia therapy trial
Clinical Trials Arena
Affimed
clinical trials
AFM283
AML
Flag link:
OncoVerity eyes cusatuzumab development in AML after licensing rights
OncoVerity eyes cusatuzumab development in AML after licensing rights
Pharmaceutical Technology
OncoVerity
Argenx
AML
cusatuzumab
Flag link:
Astellas Xospata comes up short again in bid to expand leukemia use
Astellas Xospata comes up short again in bid to expand leukemia use
Fierce Pharma
Astellas
Xospata
AML
clinical trials
Flag link:
Patient death spurs trial halt for Magenta Therapeutics
Patient death spurs trial halt for Magenta Therapeutics
Endpoints
Magenta Therapeutics
MGTA-117
clinical trials
patient deaths
AML
myelodysplastic syndrome
Flag link:
Priothera begins subject enrolment in AML therapy trial
Priothera begins subject enrolment in AML therapy trial
Clinical Trials Arena
Priothera
AML
mocravimod
Flag link:
Roche offers up to $554M in biobucks to in-need Kronos for small-molecule discovery pact
Roche offers up to $554M in biobucks to in-need Kronos for small-molecule discovery pact
Fierce Biotech
Kronos Bio
biobucks
AML
Roche
Genentech
small molecule drugs
drug discovery
Flag link:
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
Why The Magenta Therapeutics (MGTA) Stock Plummeted Over 50%
Pulse 2.0
Magenta Therapeutics
clinical trials
MGTA-117
AML
myelodysplastic syndrome
Flag link:
Rigel’s Rezlidhia (olutasidenib) Gets FDA Approval for Relapsed or Refractory AML
Rigel’s Rezlidhia (olutasidenib) Gets FDA Approval for Relapsed or Refractory AML
Xtalks
Rigel Pharmaceuticals
Rezlidhia
olutasidenib
FDA
AML
Flag link:
After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi
After nearly 20 years, Cyclacel kicks phase 3 leukemia drug back to Daiichi
Fierce Biotech
Cyclacel
AML
Sapacitabine
Daiichi Sankyo
Flag link:

Pages